Preeclampsia and HELLP syndrome as a manifestation of thrombotic microangiopathy
- Authors: Makatsaria A.D.1, Akinshina S.V.1, Bitsadze V.O.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical
- Issue: No 4 (2014)
- Pages: 4-10
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247137
- ID: 247137
Cite item
Open Access
Access granted
Abstract
Thrombotic microangiopathy is one of the severest thrombotic events, which is characterized by affected microvessels in different organs and accompanied by thrombocytopenia and hemolytic anemia. The term thrombotic microangiopathy encompasses several nosological entities characterized by different mechanisms of microthrombosis. At present, thrombotic microangiopathy includes thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, heparin-induced thrombocytopenia, and HELLP syndrome. Pregnancy is one of the most important triggers of thrombotic microangiopathy. This fact opens up broad prospects for studying the pathogenesis of thrombotic microangiopathy in the context of physiological changes in hemostasis during pregnancy. At the same time, the discovery of molecular mechanisms of thrombotic microangiopathy allows afresh look at the pathogenesis of pregnancy-associated thrombotic events and at that of the so-called placental obstetric complications, including the severe forms of preeclampsia.
Full Text
About the authors
Alexander D. Makatsaria
I.M. Sechenov First Moscow State Medical
Email: gemostasis@mail.ru
Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Svetlana V. Akinshina
I.M. Sechenov First Moscow State Medical
Email: gemostasis@mail.ru
Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Viktoria O. Bitsadze
I.M. Sechenov First Moscow State Medical
Email: gemostasis@mail.ru
Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
References
- Kentouche K., Voigt A., Schleussner E., Schneppenheim R., Budde U., Beck J.F. et al. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie. 2013; 33(2): 144-8.
- Torok T.J., Holman R.C., Chorba T.L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968-1991. Am. J. Hematol. 1995; 50: 84-90.
- Furlan M., Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract. Res. Clin. Haematol. 2001; 14(2): 437-54.
- Ruggenenti P., Noris M., Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001; 60(3): 831-46.
- Moake J.L., Rudy C.K., Troll J.H., Weinstein M.J., Colannino N.M., Azocar J. et al. Unusually large plasma factor VIII: vonWillebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1982; 307(23): 1432-5.
- Raife T., Montgomery R. New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Rev. Clin. Exp. Hematol. 2001; 5(3): 536-61.
- Lämmle B., Kremer Hovinga J., Studt J.D., Mansouri Taleghani B., Alberio L. Thrombotic thrombocytopenic purpura. Hematol. J. 2004; 5(Suppl. 3): S6-11.
- Schaller M., Studt J.D., Voorberg J., Kremer Hovinga J.A. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response. Hamostaseologie. 2013; 33(2): 121-30.
- Furlan M. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Expert Rev. Cardiovasc. Ther. 2003; 1(2): 243-55.
- George J.N. Thrombotic thrombocytopenic purpura: a syndrome that keeps evolving. J. Cli Apheresis. 2004; 19(2): 63-5.
- McCrae K.R., Cines D.B. Thrombotic microangiopathy during pregnancy. Semin. Hematol. 1997; 34(2): 148-58.
- Katz V.L., Farmer R., Kuler J.A. Preeclampsia into eclampsia: Towards a new paradigm. Am. J. Obstet. Gynecol. 2000; 182: 1389-94.
- Koenig M., Roy M., Baccot S., Cuilleron M., de Filippis J.P., Cathébras P. Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin. Rheumatol. 2005; 24(2): 166-8.
- Klonizakis P. ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status? Lupus. 2013; 22(5): 443-52.
- Pourrat O., Coudroy R., Pierre F. ADAMTS-13 deficiency in severe postpartum HELLP syndrome. Br. J. Haematol. 2013; 163(3): 409-10.
- Austin S.K., Starke R.D., Lawrie A.S., Cohen H., Machin S.J., Mackie I.J. The VWF/ADAMTS13 axis in antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br. J. Haematol. 2008; 141(4): 536-44.
- Bell W.R., Kickler T.S. Thrombocytopenia in pregnancy. Rheum. Dis. Clin. North Am. 1997; 23(1): 183-94.
- Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., Spasoff R.A. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 1991; 325(6): 393-7.
- Knöbl P.N. Treatment of thrombotic microangiopathy with a focus on new treatment options. Hamostaseologie. 2013; 33(2): 149-59.
- Lammle R., Hovinga J.A.K., Alberio L. Thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2005; 3: 1663-75.
- Isler C.M., Barrilleaux P.S., Magann E.F., Bass J.D., Martin J.N.Jr. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am. J. Obstet. Gynecol. 2001; 184(7): 1332-9.
Supplementary files
